Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Product administration interrupted? 42 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Product administration interrupted have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.0% of all adverse event reports for SECUKINUMAB.

42
Reports of Product administration interrupted with SECUKINUMAB
0.0%
of all SECUKINUMAB reports
0
Deaths
4
Hospitalizations

How Dangerous Is Product administration interrupted From SECUKINUMAB?

Of the 42 reports, 4 (9.5%) required hospitalization, and 1 (2.4%) were considered life-threatening.

Is Product administration interrupted Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 42 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Product administration interrupted?

CALCIUM OXYBATE\MAGNESIUM OXYBATE\POTASSIUM OXYBATE\SODIUM OXYBATE (1,446) SODIUM OXYBATE (1,272) CANNABIDIOL (511) ISOTRETINOIN (503) APREMILAST (314) TREPROSTINIL (295) EPOPROSTENOL (205) LENALIDOMIDE (146) ETANERCEPT (142) INTERFERON BETA-1A (115)

Which SECUKINUMAB Alternatives Have Lower Product administration interrupted Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Product administration interrupted Reports All Drugs Causing Product administration interrupted SECUKINUMAB Demographics